Ipca Laboratories Ltd Analyst Rating
based on 17 analysts
50.00%
Buy
11.11%
Hold
38.89%
Sell
Based on 17 analysts offering long term price targets for Ipca Laboratories Ltd. An average target of ₹1464.59
Source: S&P Global Market Intelligence
Ipca Laboratories Ltd Share analysis
Ipca Laboratories Ltd price forecast by 17 analysts
Downside of
High
₹1950
Target
₹1464.59
Low
₹900
Ipca Laboratories Ltd target price ₹1464.59, a slight downside of -6.98% compared to current price of ₹1573.55. According to 17 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Ipca Laboratories Ltd revenue growth forecast
Expected growth rate Q1, FY2026:32.07%
Forecast
Actual
Including amortisation and stock based compensations
Ipca Laboratories Ltd EPS growth forecast
EPS estimate Q1, FY2026:109.18%
Forecast
Actual
Source: S&P Global Market Intelligence
Ipca Laboratories Ltd Performance
Day's Low
Day's High
₹1,554.4₹1,587.552 Week's Low
52 Week's High
₹1,041₹1,708.65
| Returns % | |
| 1 Month Return | -2.47 % |
| 3 Month Return | + 11.96 % |
| 1 Year Return | + 46.48 % |
| Market Stats | |
| Previous Close | ₹1,574.50 |
| Open | ₹1,569.85 |
| Volume | 1.52L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹39,945.73Cr |
Ipca Laboratories Ltd Key Statistics
| P/E Ratio | 60.4 |
| PEG Ratio | 9.07 |
| Market Cap | ₹39,945.73 Cr |
| P/B Ratio | 4.95 |
| EPS | 20.86 |
| Dividend Yield | 0.32 |
| Sector | Pharmaceuticals |
| ROE | 9.81 |
Ipca Laboratories Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹39,945.73 Cr | 36.16% | 0.58 | ₹529 Cr | ₹7,705 Cr | |
| BUY | ₹14,159.53 Cr | -2.2% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹73,248.19 Cr | 38.18% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹95,350.73 Cr | 54.5% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹57,851.74 Cr | 23.94% | 0.53 | NA | NA |
Ipca Laboratories Ltd Mutual Fund Holdings
About Ipca Laboratories Ltd
Share Price: ₹1573.55 per share as on 21 Nov, 2024 04:01 PM
Market Capitalisation: ₹39,945.73Cr as of today
Revenue: ₹2,354.90Cr as on September 2024 (Q3 24)
Net Profit: ₹245.44Cr as on September 2024 (Q3 24)
Listing date: 03 Nov, 1994
Chairperson Name: Premchand Godha
| Organisation | Ipca Laboratories Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Ipca Laboratories Ltd
Ipca Labs Reports Strong Q2 Sales Growth - 20 Nov, 2024
Ipca Laboratories reported standalone net sales of Rs 1,810.94 crore for September 2024, marking an 8.92% year-on-year increase. The net profit for the period was Rs 244.12 crore, reflecting solid financial performance.
Ipca Laboratories Dividend and Target Price Upgrade - 18 Nov, 2024
Ipca Laboratories revised the record date for a Rs. 2 interim dividend to November 27, 2024. Additionally, Prabhudas Lilladher upgraded the stock to ACCUMULATE with a target price of Rs 1,700, citing strong revenue growth and improved margins.
IPCA Laboratories Reports Strong Q2 2024 Results - 15 Nov, 2024
IPCA Laboratories announced impressive Q2 2024 results, with revenues of ₹2354.9 crore and a profit surge of 58.2% year-over-year. Analysts maintain a positive outlook, recommending a Buy.
Ipca Laboratories Reports Strong Q2 FY25 Earnings - 14 Nov, 2024
Ipca Laboratories announced its Q2 FY25 results, showing a 15.8% increase in revenue and a 57.9% rise in net profit year-on-year. The company also declared an interim dividend of ₹21 per share. Shares rose 2.21% following the announcement, reflecting positive market sentiment.
IPCA Laboratories Shares Drop Ahead of Q2 Earnings - 13 Nov, 2024
IPCA Laboratories shares fell over 3% as investors await Q2 FY25 earnings report. Market expectations include revenue of ₹2,340 crore and net profit of ₹266 crore, reflecting cautious sentiment.
Insights on Ipca Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 7 days, IPCALAB stock has moved up by 2.5%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 59.59 Cr → 229.48 Cr (in ₹), with an average increase of 42.6% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 28.52% to 28.55% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 2.05K Cr → 2.38K Cr (in ₹), with an average increase of 7.1% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 130.6% return, outperforming this stock by 75.6%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 58.6% return, outperforming this stock by 12.1%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 46.30% of holdings in Sep 2024 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 10.85% to 10.83% in Sep 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 9.06% to 8.64% in Sep 2024 quarter
Ipca Laboratories Ltd Financials
Index Inclusions
Ipca Laboratories Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.3% | 0.00 | |
| Foreign Institutions | 10.83% | ||
| Mutual Funds | 28.55% | 0.10 | |
| Retail Investors | 8.64% | ||
| Others | 5.68% | 7.89 |
Ipca Laboratories Ltd Key Indicators
Ipca Laboratories Ltd Valuation
Ipca Laboratories Ltd in the last 5 years
Lowest (18.72x)
October 10, 2019
Industry (54.42x)
November 19, 2024
Today (60.40x)
November 19, 2024
Highest (65.89x)
September 25, 2024
Ipca Laboratories Ltd Earnings and Dividends
Ipca Laboratories Ltd Earnings Results
Ipca Laboratories Ltd’s net profit jumped 58.2% since last year same period to ₹229.48Cr in the Q2 2024-2025. On a quarterly growth basis, Ipca Laboratories Ltd has generated 19.37% jump in its net profits since last 3-months.
Read More about Earnings ResultsIpca Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Ipca Laboratories Ltd has declared dividend of ₹2 - translating a dividend yield of 0.25%.
Read More about Dividends
Ipca Laboratories Ltd Technicals Summary
Bearish
Neutral
Bullish
Ipca Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Ipca Laboratories Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Ipca Laboratories Ltd shares.
Ipca Laboratories Ltd (IPCALAB) share price today is ₹1573.55
Ipca Laboratories Ltd is listed on NSE
Ipca Laboratories Ltd is listed on BSE
- Today’s highest price of Ipca Laboratories Ltd is ₹1587.5.
- Today’s lowest price of Ipca Laboratories Ltd is ₹1554.4.
PE Ratio of Ipca Laboratories Ltd is 60.4
PE ratio = Ipca Laboratories Ltd Market price per share / Ipca Laboratories Ltd Earnings per share
Today’s traded volume of Ipca Laboratories Ltd(IPCALAB) is 1.52L.
Today’s market capitalisation of Ipca Laboratories Ltd(IPCALAB) is ₹39945.73Cr.
| Ipca Laboratories Ltd(IPCALAB | Price |
|---|---|
52 Week High | ₹1708.65 |
52 Week Low | ₹1041 |
Ipca Laboratories Ltd(IPCALAB) share price is ₹1573.55. It is down -7.91% from its 52 Week High price of ₹1708.65
Ipca Laboratories Ltd(IPCALAB) share price is ₹1573.55. It is up 51.16% from its 52 Week Low price of ₹1041
| Ipca Laboratories Ltd(IPCALAB | Returns |
|---|---|
1 Day Returns | -0.95% |
1 Month Returns | -2.47% |
3 Month Returns | 11.96% |
1 Year Returns | 46.48% |